(Q35906236)

11 August 2017

Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. (English)

1 reference

11 August 2017

Matthew T Bennett

1

1 reference

11 August 2017

Kevin W Johns

series ordinal

2

1 reference

11 August 2017

Gregory P Bondy

series ordinal

3

1 reference

11 August 2017

language of work or name

1 reference

13 June 2007

1 reference

Lipids in Health and Disease

11 August 2017

1 reference

11 August 2017

6

1 reference

11 August 2017

15

1 reference

Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929083

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929083

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929083

Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929083

Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929083

Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929083

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929083

Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients

14 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17565701

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17565701

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1476-511X-6-15

1 reference

Dimensions Publication ID

11 August 2017

0 references

1 reference

11 August 2017

PubMed publication ID

17565701

1 reference